COCM
VYGR icon

Charter Oak Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Charter Oak Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-70
Closed – – 881
2022
Q2 		$0 Hold
70
– – ﹤0.01% 1026
2022
Q1 		$1K Hold
70
– – ﹤0.01% 948
2021
Q4 		$0 Hold
70
– – ﹤0.01% 936
2021
Q3 		$0 Hold
70
– – ﹤0.01% 889
2021
Q2 		$0 Hold
70
– – ﹤0.01% 882
2021
Q1 		$0 Buy
+70
New +$477 ﹤0.01% 847

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Charter Oak Capital Management's VYGR Position: Q3 2022 in Review

Charter Oak Capital Management sold out of Voyager Therapeutics (VYGR) in Q3 2022, closing a stake of 70 shares.

Charter Oak Capital Management first reported a position in VYGR in Q1 2021 and held it in 6 quarters. The position peaked at $1K in Q1 2022. 69 funds tracked by Wall St. Rank hold VYGR as of Q3 2022.

  • Charter Oak Capital Management reported no remaining Voyager Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Charter Oak Capital Management sold 70 Voyager Therapeutics shares in Q3 2022.
  • Charter Oak Capital Management first reported a position in Voyager Therapeutics in Q1 2021 and held it in 6 quarters.
  • Charter Oak Capital Management's Voyager Therapeutics position peaked at $1K in Q1 2022.
  • 69 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.